Orit Picard
YOU?
Author Swipe
View article: Fecal and Serum Metabolome in Crohn’s Disease is Linked With Future Flare
Fecal and Serum Metabolome in Crohn’s Disease is Linked With Future Flare Open
Background Metabolites are key mediators of various physiological functions. However, there is a lack of data linking their levels to future Crohn's Disease (CD) flares. Objective We aimed to identify systemic and gut metabolic changes tha…
View article: P1314 Multi-omics analysis of Crohn’s Disease trajectory from active to remission reveals that the altered ileal anti-bacterial epithelial signals and pathogenic microbial composition and metabolomics persist despite normalizing ileal immune signals during remission
P1314 Multi-omics analysis of Crohn’s Disease trajectory from active to remission reveals that the altered ileal anti-bacterial epithelial signals and pathogenic microbial composition and metabolomics persist despite normalizing ileal immune signals during remission Open
Background Characterizing gut factors that improve or persist during Crohn’s disease (CD) trajectory from active to remission to healthy-normal states is crucial for defining treatment targets and CD cure. Methods Using multi-omics (ileal …
View article: Serum matrix metalloproteinase‐7, Syndecan‐1, and <scp>CA</scp> 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma
Serum matrix metalloproteinase‐7, Syndecan‐1, and <span>CA</span> 19‐9 as a biomarker panel for diagnosis of pancreatic ductal adenocarcinoma Open
Aims and Background Matrix metalloproteinase‐7 (MMP‐7) and Syndecan‐1 (SDC1) are involved in multiple functions during tumorigenesis. We aimed to evaluate the diagnostic and prognostic performance of these serum proteins, as potential biom…
View article: DOP09 Models for predicting Crohn Disease (CD) exacerbation using serum and fecal metabolomics
DOP09 Models for predicting Crohn Disease (CD) exacerbation using serum and fecal metabolomics Open
Background Metabolites, produced endogenously or derived from the gut microbiome, are key mediators and effectors of many cellular functions, but there are only scant data on their temporal changes along CD course. We analyzed the dynamics…
View article: Baseline Peripheral Blood Mononuclear Cell Transcriptomics Before Ustekinumab Treatment Is Linked With Crohn's Disease Clinical Response at 1 Year
Baseline Peripheral Blood Mononuclear Cell Transcriptomics Before Ustekinumab Treatment Is Linked With Crohn's Disease Clinical Response at 1 Year Open
INTRODUCTION: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL)-12 and IL-23, is used for Crohn's disease (CD), and the documented clinical remission rate after 1 year was observed in approximately 50% of patients. …
View article: Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease? Open
Background: Vedolizumab trough serum levels have been associated with clinical and endoscopic response in patients with inflammatory bowel disease (IBD). A recent study demonstrated that higher trough levels before dose escalation are asso…
View article: P004 Untargeted serum metabolome shows Crohn Disease (CD) associated signature, signals that correlate with disease activity and CRP, and signals that may precede disease flare
P004 Untargeted serum metabolome shows Crohn Disease (CD) associated signature, signals that correlate with disease activity and CRP, and signals that may precede disease flare Open
Background The serum metabolome contains potential disease biomarkers, some of which are produced endogenously, derived from the diet, or formed by the gut microbiome. We aimed to characterize metabolomics profiles linked with Crohn Diseas…
View article: P017 Fecal wash host transcriptomics identifies inflammation throughout the colon and terminal ileum
P017 Fecal wash host transcriptomics identifies inflammation throughout the colon and terminal ileum Open
Background Non-invasive modalities for assessing active endoscopic and histological inflammation in Crohn’s disease and Ulcerative Colitis patients are critically needed. Fecal wash host transcriptomics has been shown to be a robust classi…
View article: P056 Exposures linked with urban and rural living indicate that living in rural area but spending above 50% of daily-life in urban environment is linked with reduction in alpha-diversity, reduced rural index, and reduced microbial health index mirroring CD profile
P056 Exposures linked with urban and rural living indicate that living in rural area but spending above 50% of daily-life in urban environment is linked with reduction in alpha-diversity, reduced rural index, and reduced microbial health index mirroring CD profile Open
Background Efforts to delineate factors linked with rural to urban transition, paralleling the staggering rise in CD incidence, have been hampered by the universal modernization in the west. China is ongoing transition from a predominantly…
View article: P046 Crohn Disease (CD) untargeted fecal metabolome shows strong correlation with specific salivary associated microbial taxa, and with disease activity
P046 Crohn Disease (CD) untargeted fecal metabolome shows strong correlation with specific salivary associated microbial taxa, and with disease activity Open
Background The fecal metabolome is comprised from derivatives of the gut microbiome, the host, the environment, and the diet. Thus, it is a central output and effector that is linked with Crohn disease (CD). We aimed to characterize metabo…
View article: Distal Fecal Wash Host Transcriptomics Identifies Inflammation Throughout the Colon and Terminal Ileum
Distal Fecal Wash Host Transcriptomics Identifies Inflammation Throughout the Colon and Terminal Ileum Open
Our study establishes the accuracy of distal colonic fecal washes for identifying and scoring inflammatory processes throughout the entire ileal-colonic axis.
View article: Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome
Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome Open
Background Human telomerase reverse transcriptase (hTERT)- mRNA was shown to be elevated in exosomes derived from the sera of a variety of hematological and solid cancer patients. We aimed to evaluate its role as a diagnostic marker in pat…
View article: Immune function in newborns with in-utero exposure to anti-TNFα therapy
Immune function in newborns with in-utero exposure to anti-TNFα therapy Open
Background and aim Anti-TNFα is measurable in infants exposed in utero up to 12 months of age. Data about the exposure effect on the infant’s adaptive immunity are limited. We aimed to prospectively evaluate the distribution and function o…
View article: Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma
Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma Open
INTRODUCTION: Syndecan-1 (SDC1) has multiple functions in tumorigenesis in general and specifically in pancreatic cancer. We aimed to evaluate SDC1 as a diagnostic and prognostic biomarker in patients with pancreatic ductal adenocarcinoma …
View article: HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B Open
A comprehensive characterization of chronic HBV (CHB) patients is required to guide therapeutic decisions. The cumulative impact of classical and novel biomarkers on the clinical categorization of these patients has not been rigorously ass…
View article: OP31 Dietary and Multi-Omic characterization of new onset treatment naive Crohn Disease identifies factors that may contribute to disease pathogenesis
OP31 Dietary and Multi-Omic characterization of new onset treatment naive Crohn Disease identifies factors that may contribute to disease pathogenesis Open
Background Crohn Disease (CD) prevalence is rising worldwide. As altered genetics are improbable, this phenomenon likely relates to environmental-dietary changes linked with gut microbiome. We aimed to define host and microbial factors at …
View article: P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease? Open
Background Vedolizumab trough serum levels have been associated with clinical and endoscopic response in patients with inflammatory bowel disease (IBD), albeit findings have not been conclusive. A recent study demonstrated that higher trou…
View article: Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening
Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening Open
Background: Higher infliximab trough levels (TLs) correlate with better clinical, inflammatory, and endoscopic outcomes among inflammatory bowel disease (IBD) patients. Although standard scheduled infliximab therapy regimen consists of inf…
View article: P032 Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients
P032 Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients Open
Background Colonoscopy is the gold standard for evaluation of inflammation in inflammatory bowel diseases (IBD), yet entails cumbersome preparations and risks of injury. Existing non-invasive prognostic tools are limited in their diagnosti…
View article: P014 Untargeted serum metabolome in longitudinal Crohn’s Disease (CD) cohort enrolled during remission shows strong individualized signature and CD-associated signals that are maintained also in patients who normalized their fecal calprotectin
P014 Untargeted serum metabolome in longitudinal Crohn’s Disease (CD) cohort enrolled during remission shows strong individualized signature and CD-associated signals that are maintained also in patients who normalized their fecal calprotectin Open
Background The serum metabolome contains potential disease biomarkers, some of which are produced endogenously, and some are generated by the gut microbiome. We recently found that Crohn’s Disease (CD) patients in remission still show sign…
View article: Lessons from intensified surveillance of viral hepatitis A, Israel, 2017 and 2018
Lessons from intensified surveillance of viral hepatitis A, Israel, 2017 and 2018 Open
Introduction Universal vaccination of toddlers has led to very low hepatitis A (HAV) endemicity in Israel. However, sporadic outbreaks still occur, necessitating better surveillance. Aim To implement a comprehensive HAV surveillance progra…
View article: SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses
SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses Open
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic is still ongoing along with the global vaccination efforts against it. Here, we aimed to understand the longevity and strength of anti-SARS-CoV-2 IgG responses in a smal…
View article: Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease
Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease Open
Background Immunomodulators and anti tumor-necrosis-α antibodies (anti-TNFs) have been implicated in increased risk of Epstein–Barr virus (EBV)–driven B-cell lymphoproliferative disorders in inflammatory bowel disease (IBD) patients. Howev…
View article: P177 Lower vedolizumab trough levels before interval shortening are not predictive of success of the intervention
P177 Lower vedolizumab trough levels before interval shortening are not predictive of success of the intervention Open
Background Pharmacokinetics of vedolizumab have been associated with therapy outcome, although real-life data has been contradictory. Thus, we set to examine whether vedolizumab levels before therapy intensification may be associated with …
View article: P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels
P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels Open
Background An association between higher infliximab-trough-levels (TL) and better outcomes has been demonstrated among IBD patients. Although standard scheduled infliximab therapy regimen consists of infusions at pre-defined time-points (w…
View article: P012 α4β7 Receptor occupancy by vedolizumab at trough time-point occurs at the membranal level and is not associated with endoscopic healing in inflammatory bowel disease patients
P012 α4β7 Receptor occupancy by vedolizumab at trough time-point occurs at the membranal level and is not associated with endoscopic healing in inflammatory bowel disease patients Open
Background Previous studies have shown inconclusive associations between vedolizumab trough levels and therapy outcomes. A near-complete occupancy of blood and intestinal α4β7 was exerted by vedolizumab through a wide-range of drug levels,…
View article: Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists
Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists Open
Drugs formulated from monoclonal antibodies (mAbs) are clinically effective in various diseases. Repeated administration of mAbs, however, elicits an immune response in the form of anti-drug-antibodies (ADA), thereby reducing the drug's ef…